Quantcast
Home > Quotes > MEIP

MEI Pharma, Inc. Common Stock (MEIP) Quote & Summary Data

MEIP 
$2.85
*  
0.07
2.52%
Get MEIP Alerts
*Delayed - data as of Feb. 21, 2019 15:37 ET  -  Find a broker to begin trading MEIP now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MEIP Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.84 / $ 2.86
1 Year Target
7.5
Today's High / Low
$ 2.94 / $ 2.72
Share Volume
154,450
50 Day Avg. Daily Volume
235,346
Previous Close
$ 2.78
52 Week High / Low
$ 5.14 / $ 1.82
Market Cap
202,775,055
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.16

Intraday Chart

Shares Traded

Share Volume:
154,450
50 Day Avg. Daily Volume:
235,346

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.88

Trading Range

The current last sale of $2.85 is 56.59% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.94 $ 5.14
 Low: $ 2.72 $ 1.82

Company Description (as filed with the SEC)

We are a pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four clinical-stage candidates, including one candidate in an ongoing Phase 3 global registration trial and another candidate that is anticipated to advance, in the fourth calendar quarter of calendar year 2018, into a Phase 2 clinical trial that we intend to submit to the U.S. Food and Drug Administration ("FDA") as support for accelerated approval of a marketing application. Our common stock is listed on the NASDAQ Capital Market under the symbol "MEIP". Our Strategy Our focus is on developing and commercializing cancer treatments intended to effectively leverage the potential of a mechanism of action to provide increased benefit to patients.  ... More ...  


Risk Grade

Where does MEIP fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.78
Open Date:
Feb. 21, 2019
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info